Zebin Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zebin Wen has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Guanchuan Lin
Southern Medical University, and Guangdong Provincial Key Laboratory of Single Cell Technology and Application Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences Guangzhou 510515
2 shared publications - Itay Tirosh
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
2 shared publications - Mario L. Suva
Department of Pathology and Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
2 shared publications - Xinghua Pan
Precision Regenerative Medicine Research Centre, Medical Science Division, and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, 999078, Macao Special Administrative Region of China
2 shared publications - Adriana E. Tron
Servier BioInnovations, Boston, MA, USA
1 shared publication - Aleksandra B. Lasica
Harvard Medical School , Boston, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Elsevier in Cancer Cell
- Vol. 44 (9) , 1882-1892.e7
Spatial analysis reveals the evolving organization of IDH-mutant glioma
- 14 September 2026
- Published by Elsevier in Cancer Cell
- Vol. 44 (9) , 1882-1892.e7
Open AccessSpatial analysis reveals the evolving organization of IDH-mutant glioma
- 5 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (861)
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma
The mutant isocitrate dehydrogenase 1/2 inhibitor (mIDHi) vorasidenib was recently incorporated into clinical treatment guidelines for IDH-mutant gliomas, although its impact on chemoradiation is unclear. Specifically, it is unknown whether upfront mIDHi exposure alters subsequent chemoradiation efficacy. Addressing this critical question has been challenging because of limited clinical data and a paucity of mIDHi-responsive preclinical glioma models. We first established that a genetic mouse model of IDH-mutant astrocytoma developed by our group was responsive to vorasidenib monotherapy. We then used this mouse to address whether mIDHi alters the response to chemoradiation after progression on mIDHi. Mice that received upfront vorasidenib followed by chemoradiation at progression had improved survival compared with control mice receiving vehicle followed by chemoradiation. We then compiled real-world data and early outcomes from 29 patients who were among the first to receive mIDHi followed by radiation with or without chemotherapy. Our study directly addresses uncertainty surrounding therapy sequencing that has emerged after introduction of vorasidenib as a first-line treatment for IDH-mutant glioma. Our empirical preclinical data demonstrate that prior mIDHi treatment enhances chemoradiation sensitivity of IDH-mutant glioma.
- 5 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (861)
Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma
The mutant isocitrate dehydrogenase 1/2 inhibitor (mIDHi) vorasidenib was recently incorporated into clinical treatment guidelines for IDH-mutant gliomas, although its impact on chemoradiation is unclear. Specifically, it is unknown whether upfront mIDHi exposure alters subsequent chemoradiation efficacy. Addressing this critical question has been challenging because of limited clinical data and a paucity of mIDHi-responsive preclinical glioma models. We first established that a genetic mouse model of IDH-mutant astrocytoma developed by our group was responsive to vorasidenib monotherapy. We then used this mouse to address whether mIDHi alters the response to chemoradiation after progression on mIDHi. Mice that received upfront vorasidenib followed by chemoradiation at progression had improved survival compared with control mice receiving vehicle followed by chemoradiation. We then compiled real-world data and early outcomes from 29 patients who were among the first to receive mIDHi followed by radiation with or without chemotherapy. Our study directly addresses uncertainty surrounding therapy sequencing that has emerged after introduction of vorasidenib as a first-line treatment for IDH-mutant glioma. Our empirical preclinical data demonstrate that prior mIDHi treatment enhances chemoradiation sensitivity of IDH-mutant glioma.
- Open Access
- 2 December 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
Profiling Cell-state Fingerprints Based on Deep Learning Model with Meta-programs of Pan-cancer
Cell states within cancer have garnered significant attention, yet the mechanisms through which malignant cells assert dominance in pan-cancer commonalities remain elusive. In this study, we employed label-free multiplexed single-cell RNA sequencing (scRNA-seq) to analyze cell states in 159,372 cells across 245 cell lines spanning 14 tissue types, integrating both public and proprietary datasets. We identified 21 meta-programs (MPs) representing shared characteristics across pan-cancer landscapes, encompassing 16 biological processes. Subsequently, we developed a deep learning model StateNet to generate cell-state fingerprints for delineating the individuality of each cell line based on these MPs. Leveraging StateNet, we pinpointed ACAT2 as a potential mediator bridging hypoxia and the lipid metabolism pathway, and we also showcased that epithelial–mesenchymal transition programs are vital for classifying cell lines through perturbation experiments. StateNet not only elucidates the overarching manifold structure of scRNA-seq data but also furnishes cell-state fingerprints of cell clusters, unveiling prognosis-related programs and distinguishing between patients with varying survival outcomes. Utilizing these prognosis-related programs on 3210 cancer samples, we constructed Cox models and identified risk-associated programs and genes responsible for different cancer types. StateNet thus emerges as a novel and efficient tool for cancer profiling, unraveling the shared commonalities and distinct individualities of pan-cancer cells across expansive datasets.
- 2 December 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
Open AccessProfiling Cell-state Fingerprints Based on Deep Learning Model with Meta-programs of Pan-cancer
Cell states within cancer have garnered significant attention, yet the mechanisms through which malignant cells assert dominance in pan-cancer commonalities remain elusive. In this study, we employed label-free multiplexed single-cell RNA sequencing (scRNA-seq) to analyze cell states in 159,372 cells across 245 cell lines spanning 14 tissue types, integrating both public and proprietary datasets. We identified 21 meta-programs (MPs) representing shared characteristics across pan-cancer landscapes, encompassing 16 biological processes. Subsequently, we developed a deep learning model StateNet to generate cell-state fingerprints for delineating the individuality of each cell line based on these MPs. Leveraging StateNet, we pinpointed ACAT2 as a potential mediator bridging hypoxia and the lipid metabolism pathway, and we also showcased that epithelial–mesenchymal transition programs are vital for classifying cell lines through perturbation experiments. StateNet not only elucidates the overarching manifold structure of scRNA-seq data but also furnishes cell-state fingerprints of cell clusters, unveiling prognosis-related programs and distinguishing between patients with varying survival outcomes. Utilizing these prognosis-related programs on 3210 cancer samples, we constructed Cox models and identified risk-associated programs and genes responsible for different cancer types. StateNet thus emerges as a novel and efficient tool for cancer profiling, unraveling the shared commonalities and distinct individualities of pan-cancer cells across expansive datasets.
- Open Access
Shortcut barcoding and early pooling for scalable multiplex single-cell reduced-representation CpG methylation sequencing at single nucleotide resolution
DNA methylation is essential for a wide variety of biological processes, yet the development of a highly efficient and robust technology remains a challenge for routine single-cell analysis. We developed a multiplex scalable single-cell reduced representation bisulfite sequencing (msRRBS) technology with off-the-shelf reagents and equipment. It allows cell-specific barcoded DNA fragments of individual cells to be pooled before bisulfite conversion, free of enzymatic modification or physical capture of the DNA ends, and achieves unparalleled read mapping rates of 62.51%, covering 59.95% of CpG islands and 71.62% of promoters in K562 cells on average. Its reproducibility is shown in duplicates of bulk cells with near perfect correlation (R=0.97-99). At a low 1 Mb of clean reads, msRRBS provides consistent coverage of CpG islands and promoters, outperforming the conventional methods with orders of magnitude reduction in cost. Here, we use this method to characterize the distinct methylation patterns and cellular heterogeneity of 6 cell lines, and leukemia and hepatocellular carcinoma models. Taking 4 hours of hands-on time, msRRBS offers a unique, highly efficient approach for dissecting methylation heterogeneity in a variety of multicellular systems.
Open AccessShortcut barcoding and early pooling for scalable multiplex single-cell reduced-representation CpG methylation sequencing at single nucleotide resolution
DNA methylation is essential for a wide variety of biological processes, yet the development of a highly efficient and robust technology remains a challenge for routine single-cell analysis. We developed a multiplex scalable single-cell reduced representation bisulfite sequencing (msRRBS) technology with off-the-shelf reagents and equipment. It allows cell-specific barcoded DNA fragments of individual cells to be pooled before bisulfite conversion, free of enzymatic modification or physical capture of the DNA ends, and achieves unparalleled read mapping rates of 62.51%, covering 59.95% of CpG islands and 71.62% of promoters in K562 cells on average. Its reproducibility is shown in duplicates of bulk cells with near perfect correlation (R=0.97-99). At a low 1 Mb of clean reads, msRRBS provides consistent coverage of CpG islands and promoters, outperforming the conventional methods with orders of magnitude reduction in cost. Here, we use this method to characterize the distinct methylation patterns and cellular heterogeneity of 6 cell lines, and leukemia and hepatocellular carcinoma models. Taking 4 hours of hands-on time, msRRBS offers a unique, highly efficient approach for dissecting methylation heterogeneity in a variety of multicellular systems.